{"id":"NCT01798706","sponsor":"Sanofi","briefTitle":"Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients","officialTitle":"A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter, 24 Week Study Assessing the Safety and Efficacy of Lixisenatide in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Diabetes Treatment Regimen","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06","primaryCompletion":"2015-02","completion":"2015-02","firstPosted":"2013-02-26","resultsPosted":"2016-10-14","lastUpdate":"2017-04-18"},"enrollment":350,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Lixisenatide (AVE0010)","otherNames":["Lyxumia"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Antidiabetic background therapy","otherNames":[]}],"arms":[{"label":"Lixisenatide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Primary objective:\n\n\\- To evaluate the effect of lixisenatide versus placebo over a period of 24 weeks on glycemic control, as evaluated by glycosylated hemoglobin (HbA1c) reduction, in older type 2 diabetes participants (T2DM) who are inadequately controlled with their current anti-diabetic treatment regimen.\n\nMain secondary objective:\n\n\\- To assess the safety and tolerability of lixisenatide compared to placebo in older T2DM participants (including occurrence of documented (Plasma Glucose PG \\< 60 mg/dL) symptomatic hypoglycemia and gastrointestinal side effects).\n\nOther secondary objectives:\n\n* To assess the effect of lixisenatide compared to placebo after 24-week treatment on:\n\n  * Fasting plasma glucose (FPG);\n  * During liquid standardized breakfast meal challenge test : 2 hour- Postprandial Plasma Glucose (PPG) and Plasma Glucose Excursion;\n  * 7-point Self-monitored plasma glucose (SMPG) profile;\n  * Body weight;\n  * Change in total daily dose of basal insulin (if taken);\n  * Percentage of participants requiring rescue therapy\n  * Safety and tolerability;\n* To assess lixisenatide pharmacokinetic profile;\n* To assess anti-lixisenatide antibody development.","primaryOutcome":{"measure":"Absolute Change in HbA1c From Baseline to Week 24","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Lixisenatide","deltaMin":-0.57,"sd":0.075},{"arm":"Placebo","deltaMin":0.06,"sd":0.072}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"70 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":18},"locations":{"siteCount":83,"countries":["United States","Australia","Bulgaria","Canada","Denmark","Germany","Norway","Peru","Poland","South Africa","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["28188240","39963952"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":176},"commonTop":["Nausea","Hypoglycaemia","Nasopharyngitis","Diarrhoea","Headache"]}}